Children Undergoing Liver Transplantation for Treatment of Inherited Metabolic Diseases Are Prone to Higher Oxidative Stress, Complement Activity and Transforming Growth Factor-β1
Overview
Authors
Affiliations
Background: Main indications for liver transplantation in the pediatric population include biliary atresia and inherited metabolic diseases. The present study evaluated whether there are differences between pediatric patients undergoing living-related liver transplantation due to the two diseases in terms of their oxidative and immunological status during their regular outpatient follow-up visits.
Material And Methods: A clinical outpatient study measuring serum oxidative stress index (calculated as serum oxidant/antioxidant ratio, in the form of serum total hydroperoxide/serum biological antioxidative potential), serum terminal complement component 5a, as an indicator of complement activity and immunological status, and transforming growth factor-ß1, as a marker of liver fibrosis, in 16 patients (6 males and 10 females, 2.5-15 years old) who received living-related liver transplantation due to inherited metabolic diseases (n=6; in the form of propionic acidemia [n=1], methylmalonic acidemia [n=1], arginase deficiency [n=1], tyrosinemia [n=2], and glycogen storage disease type 1b [n=1], with an age range of 2.4-14.6 years old) and due to biliary atresia ([n=10], with an age range of 2.9-14.5 years old).
Results: Serum oxidative stress index, complement component-5a, and transforming growth factor-ß1 were significantly higher in the inherited metabolic diseases group than in the biliary atresia group. In all patients, serum oxidative stress index correlated positively with complement component-5a and transforming growth factor-ß1.
Conclusions: Patients who receive living-related liver transplantation due to inherited metabolic diseases are prone to higher oxidative stress, complement activity, and serum transforming growth factor-ß1.
Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients.
Aktuglu Zeybek A, Kiykim E, Neselioglu S, Iscan H, Zubarioglu T, Cansever M Pediatr Res. 2021; 92(2):474-479.
PMID: 34628487 DOI: 10.1038/s41390-021-01770-6.
Ilyinskii P, Michaud A, Rizzo G, Roy C, Leung S, Elkins S Mol Ther Methods Clin Dev. 2021; 22:279-292.
PMID: 34485611 PMC: 8399083. DOI: 10.1016/j.omtm.2021.06.015.
Oxidative Stress Indexes for Diagnosis of Health or Disease in Humans.
Sanchez-Rodriguez M, Mendoza-Nunez V Oxid Med Cell Longev. 2019; 2019:4128152.
PMID: 31885788 PMC: 6899293. DOI: 10.1155/2019/4128152.
Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia.
An D, Frassetto A, Jacquinet E, Eybye M, Milano J, DeAntonis C EBioMedicine. 2019; 45:519-528.
PMID: 31303505 PMC: 6642332. DOI: 10.1016/j.ebiom.2019.07.003.
Label-Free Quantitative Proteomics in a Methylmalonyl-CoA Mutase-Silenced Neuroblastoma Cell Line.
Costanzo M, Cevenini A, Marchese E, Imperlini E, Raia M, Del Vecchio L Int J Mol Sci. 2018; 19(11).
PMID: 30428564 PMC: 6275031. DOI: 10.3390/ijms19113580.